221 related articles for article (PubMed ID: 32914297)
1. Hepatitis C virus-associated decompensated liver cirrhosis with refractory hepatic encephalopathy successfully treated by balloon-occluded retrograde transvenous obliteration after sofosbuvir/velpatasvir.
Takakusagi S; Shimizu M; Yokoyama Y; Kizawa K; Marubashi K; Kosone T; Sato K; Kakizaki S; Takagi H; Uraoka T
Clin J Gastroenterol; 2020 Dec; 13(6):1303-1309. PubMed ID: 32914297
[TBL] [Abstract][Full Text] [Related]
2. Novel Therapeutic Strategy Using Interventional Radiology (IVR) for Hepatitis C Virus (HCV)-Related Decompensated Liver Cirrhosis: A Case Report.
Iwamoto T; Saeki I; Hidaka I; Ishikawa T; Takami T; Sakaida I
Am J Case Rep; 2019 Nov; 20():1699-1704. PubMed ID: 31738743
[TBL] [Abstract][Full Text] [Related]
3. Real-world effectiveness of daclatasvir plus sofosbuvir and velpatasvir/sofosbuvir in hepatitis C genotype 2 and 3.
Belperio PS; Shahoumian TA; Loomis TP; Mole LA; Backus LI
J Hepatol; 2019 Jan; 70(1):15-23. PubMed ID: 30266283
[TBL] [Abstract][Full Text] [Related]
4. Real-world clinical outcomes of sofosbuvir and velpatasvir treatment in HCV genotype 1- and 2-infected patients with decompensated cirrhosis: A nationwide multicenter study by the Japanese Red Cross Liver Study Group.
Tada T; Kurosaki M; Nakamura S; Hasebe C; Kojima Y; Furuta K; Kobashi H; Kimura H; Ogawa C; Yagisawa H; Uchida Y; Joko K; Akahane T; Arai H; Marusawa H; Narita R; Ide Y; Sato T; Kusakabe A; Tsuji K; Mori N; Kondo M; Mitsuda A; Izumi N
J Med Virol; 2021 Nov; 93(11):6247-6256. PubMed ID: 34170517
[TBL] [Abstract][Full Text] [Related]
5. Successful prolonged treatment with sofosbuvir/velpatasvir for a hepatitis C patient with decompensated cirrhosis and treatment failure after 12-week therapy.
Suzuki H; Sato K; Takezawa J; Yamada S; Uraoka T; Okamoto H
Clin J Gastroenterol; 2024 Feb; 17(1):106-111. PubMed ID: 37792179
[TBL] [Abstract][Full Text] [Related]
6. Sofosbuvir plus velpatasvir treatment for hepatitis C virus in patients with decompensated cirrhosis: a Japanese real-world multicenter study.
Tahata Y; Hikita H; Mochida S; Kawada N; Enomoto N; Ido A; Yoshiji H; Miki D; Hiasa Y; Takikawa Y; Sakamori R; Kurosaki M; Yatsuhashi H; Tateishi R; Ueno Y; Itoh Y; Yamashita T; Kanto T; Suda G; Nakamoto Y; Kato N; Asahina Y; Matsuura K; Terai S; Nakao K; Shimizu M; Takami T; Akuta N; Yamada R; Kodama T; Tatsumi T; Yamada T; Takehara T
J Gastroenterol; 2021 Jan; 56(1):67-77. PubMed ID: 33001338
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness analysis of sofosbuvir and velpatasvir in chronic hepatitis C patients with decompensated cirrhosis.
Chan J; Kim JJ; Barrett BK; Hamadeh A; Feld JJ; Wong WWL
J Viral Hepat; 2021 Feb; 28(2):260-267. PubMed ID: 33065774
[TBL] [Abstract][Full Text] [Related]
8. [Effectiveness and safety of sofosbuvir/velpatasvir combination ± ribavirin in the treatment of Chinese adults with chronic hepatitis C virus infection].
Li JP; Chen XF; Yan Q; Zhang YJ; Xie ZW; Xia Y; Guan YJ
Zhonghua Gan Zang Bing Za Zhi; 2020 Oct; 28(10):831-837. PubMed ID: 33105927
[No Abstract] [Full Text] [Related]
9. Sustained virologic response rates in patients with chronic hepatitis C genotype 6 treated with ledipasvir+sofosbuvir or sofosbuvir+velpatasvir.
Nguyen E; Trinh S; Trinh H; Nguyen H; Nguyen K; Do A; Levitt B; Do S; Nguyen M; Purohit T; Shieh E; Nguyen MH
Aliment Pharmacol Ther; 2019 Jan; 49(1):99-106. PubMed ID: 30467877
[TBL] [Abstract][Full Text] [Related]
10. Intractable hepatic encephalopathy in cirrhotic patients: mid-term efficacy of balloon-occluded retrograde portosystemic shunt obliteration.
Mukund A; Chalamarla LK; Singla N; Shasthry SM; Sarin SK
Eur Radiol; 2020 Jun; 30(6):3462-3472. PubMed ID: 32048037
[TBL] [Abstract][Full Text] [Related]
11. A Hepatitis C Virus-Associated Decompensated Cirrhotic Patient Who Showed the Disappearance of Hepatic Encephalopathy, Ascites, and Pleural Effusion by Antiviral Therapy with Sofosbuvir/Velpatasvir.
Tarao K; Nozaki A; Komatsu H
Case Rep Gastroenterol; 2021; 15(1):436-442. PubMed ID: 34054397
[TBL] [Abstract][Full Text] [Related]
12. Effectiveness and safety of sofosbuvir/velpatasvir/voxilaprevir in patients with chronic hepatitis C previously treated with DAAs.
Llaneras J; Riveiro-Barciela M; Lens S; Diago M; Cachero A; García-Samaniego J; Conde I; Arencibia A; Arenas J; Gea F; Torras X; Luis Calleja J; Antonio Carrión J; Fernández I; María Morillas R; Rosales JM; Carmona I; Fernández-Rodríguez C; Hernández-Guerra M; Llerena S; Bernal V; Turnes J; González-Santiago JM; Montoliu S; Figueruela B; Badia E; Delgado M; Fernández-Bermejo M; Iñarrairaegui M; Pascasio JM; Esteban R; Mariño Z; Buti M
J Hepatol; 2019 Oct; 71(4):666-672. PubMed ID: 31203153
[TBL] [Abstract][Full Text] [Related]
13. Improved Hepatic Reserve and Fibrosis in a Case of "Portal-Systemic Liver Failure" by Portosystemic Shunt Occlusion.
Ishikawa T; Sasaki R; Nishimura T; Iwamoto T; Takami T; Yamasaki T; Sakaida I
Am J Case Rep; 2020 Feb; 21():e921236. PubMed ID: 32063601
[TBL] [Abstract][Full Text] [Related]
14. Real-world effectiveness and safety of sofosbuvir/velpatasvir and ledipasvir/sofosbuvir hepatitis C treatment in a single centre in Germany.
Buggisch P; Wursthorn K; Stoehr A; Atanasov PK; Supiot R; Lee J; Ting J; Petersen J
PLoS One; 2019; 14(4):e0214795. PubMed ID: 30946776
[TBL] [Abstract][Full Text] [Related]
15. Short-term hepatocyte function and portal hypertension outcomes of sofosbuvir/velpatasvir for decompensated hepatitis C-related cirrhosis.
Kotani K; Enomoto M; Uchida-Kobayashi S; Tamori A; Yukawa-Muto Y; Odagiri N; Motoyama H; Kozuka R; Kawamura E; Hagihara A; Fujii H; Kageyama K; Yamamoto A; Yoshida A; Higashiyama S; Kawabe J; Kawada N
J Gastroenterol; 2023 Apr; 58(4):394-404. PubMed ID: 36729172
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of balloon-occluded retrograde transvenous obliteration of large spontaneous lienorenal shunt in patients with severe recurrent hepatic encephalopathy with foam sclerotherapy: initial experience.
Mukund A; Rajesh S; Arora A; Patidar Y; Jain D; Sarin SK
J Vasc Interv Radiol; 2012 Sep; 23(9):1200-6. PubMed ID: 22832139
[TBL] [Abstract][Full Text] [Related]
17. Significant improvement in portal-systemic liver failure symptoms and successful management of portal-splenic venous hemodynamics by the combination of interventional radiology and pharmacotherapy.
Ishikawa T; Hamamoto K; Sasaki R; Nishimura T; Matsuda T; Iwamoto T; Takami T; Sakaida I
Hepatol Res; 2020 Oct; 50(10):1201-1208. PubMed ID: 32609922
[TBL] [Abstract][Full Text] [Related]
18. Real-life effectiveness and safety of sofosbuvir/velpatasvir/voxilaprevir in hepatitis C patients with previous DAA failure.
Degasperi E; Spinetti A; Lombardi A; Landonio S; Rossi MC; Pasulo L; Pozzoni P; Giorgini A; Fabris P; Romano A; Lomonaco L; Puoti M; Vinci M; Gatti F; Carolo G; Zoncada A; Bonfanti P; Russo FP; Aghemo A; Soria A; Centenaro R; Maggiolo F; Rovere P; Pasin F; Paon V; Faggiano G; Vario A; Grossi G; Soffredini R; Carriero C; Paolucci S; Noventa F; Alberti A; Lampertico P; Fagiuoli S;
J Hepatol; 2019 Dec; 71(6):1106-1115. PubMed ID: 31433303
[TBL] [Abstract][Full Text] [Related]
19. Sofosbuvir/velpatasvir improves patient-reported outcomes in HCV patients: Results from ASTRAL-1 placebo-controlled trial.
Younossi ZM; Stepanova M; Feld J; Zeuzem S; Jacobson I; Agarwal K; Hezode C; Nader F; Henry L; Hunt S
J Hepatol; 2016 Jul; 65(1):33-39. PubMed ID: 26956698
[TBL] [Abstract][Full Text] [Related]
20. Portal-systemic Encephalopathy due to Complicated Spleno-renal Shunt Successfully Treated with Balloon-occluded Retrograde Transvenous Obliteration Using a Double Coaxial Balloon Catheter System and Shape-memory Coils.
Matsuoka S; Yamana Y; Ishii T; Kumagawa M; Mizutani T; Kamimura S; Matsumoto N; Nakamura H; Nirei K; Tatsuo K; Moriyama M
Intern Med; 2018 Jul; 57(13):1861-1866. PubMed ID: 29491295
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
